Pharmacokinetics of recombinant interferon-alpha 2 following intralesional administration in malignant glioma patients.
Pharmacokinetics of recombinant interferon-alpha 2 (rIFN-alpha 2) following intralesional administration into patients with malignant gliomas was investigated. A dose of 5 X 10(6) IU of rIFN-alpha 2 was injected locally postoperatively for 2 weeks each day, and the same dose was then given once a week for 10 additional weeks. During the daily and weekly administration, the IFN was consistently present in the fluid of the postsurgical cavity. Not until 5 weeks after the end of the IFN administration was the IFN undetectable. The decay of IFN injected was minimal.
D000328:Adult; D001932:Brain Neoplasms / Q000378:metabolism / Q000628:therapy*; D005260:Female; D005910:Glioma / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000378:metabolism; D007700:Kinetics; D008297:Male; D008875:Middle Aged
D007370:Interferon Type I